Please ensure Javascript is enabled for purposes of website accessibility

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

By Todd Campbell – Sep 17, 2020 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.

Bristol-Myers Squibb (BMY -0.33%) is granting Dr. Reddy's Laboratories (RDY 0.13%) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022.

Previously, Bristol-Myers filed a patent-infringement lawsuit against Dr. Reddy's in an attempt to prevent the healthcare company from launching its generic version of Revlimid. In the second quarter, Revlimid produced $2.9 billion in revenue for Bristol-Myers.

A man speaking through a megaphone.

IMAGE SOURCE: GETTY IMAGES.

The newly inked agreement gives Dr. Reddy's the right to produce a limited amount of Revlimid beginning on an undisclosed date following March 2022, when an agreement with another generic drugmaker -- Natco -- kicks in. Restrictions limiting Dr. Reddy's production volume disappear on January 31, 2026.

The agreement allows Bristol-Myers to control how quickly Revlimid's revenue declines following its patent expiration, while also removing costs and uncertainty relating to Bristol-Myers litigation. Bristol-Myers acquired Revlimid when it bought Celgene in 2019 for approximately $74 billion.

There are over 32,000 patients diagnosed with multiple myeloma annually in the United States, making it the second most common blood cancer in the country.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned.  The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Stocks Mentioned

Bristol-Myers Squibb Stock Quote
Bristol-Myers Squibb
BMY
$79.67 (-0.33%) $0.26
Dr. Reddys Laboratories Stock Quote
Dr. Reddys Laboratories
RDY
$53.32 (0.13%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.